Identification and characterization of anti-prionic compounds that disassemble Tau prions as a novel therapeutic approach for tauopathies
Objective: Stabilization of monomeric Tau protein by transient and high-affinity binding ligands is a novel and highly innovative anti-prionic treatment strategy for tauopathies. Background: Tauopathies…Budget Impact of Apomorphine Sublingual Film for On-Demand Treatment of Patients With Parkinson’s Disease and “OFF” Episodes
Objective: To estimate the budget impact of introducing apomorphine sublingual film (APL-130277; APL) as an on-demand treatment for patients with Parkinson’s disease (PD) and “OFF”…Onset of Drug-Related Adverse Events in Parkinson’s Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis
Objective: This post-hoc analysis investigated the onset of treatment-emergent adverse events (TEAEs) that were considered at least possibly related to opicapone (OPC) treatment. Background: OPC…Refractory tremor: is perampanel a potentially useful therapy?
Objective: To describe our series of patients with refractory tremor eventually treated with perampanel and to analyse its clinical outcomes. Background: Up to 40% of…Long-term levodopa-carbidopa intestinal infusion in Parkinson’s disease: survival and mortality
Objective: We sought to analyze the mortality and the causes of death of 105 patients with Parkinson disease (PD) treated with levodopa-carbidopa intestinal gel (LCIG)…The Effect of Gocovri on Motor Aspects of Experiences of Daily Living: Analyses of MDS-UPDRS Part II Data from a Phase 3 Program
Objective: To assess the impact of Gocovri® (amantadine) extended release capsules on motor aspects of experiences of daily living in PD patients. Background: Gocovri is…The Efficacy and Safety of Gocovri Based on Age: Special Population Analyses of a Phase 3 Study Program
Objective: To assess patient outcomes and adverse events in Parkinson’s disease (PD) patients treated with Gocovri® (amantadine) extended release capsules at bedtime for dyskinesia, by…Preclinical profile of dopamine D1PAM: A novel mechanism in clinical development for Lewy Body dementia
Objective: Introduce the mechanism of action for dopamine D1 positive allosteric modulator (D1PAM) as a new target for neuropsychiatric disorders. Describe the preclinical profile of…Parkinson Kinetigraph – does it change the management of PD patients?
Objective: This pragmatic randomized open trial evaluated if the information from a Parkinson Kinetigraph (PKG) recording changed the management of PD patients at a visit…Analysis of the Shape of the Gocovri Steady-state PK Profile: Implications for an Extended Release Product
Objective: To demonstrate the unique shape and pharmacokinetic (PK) profile of Gocovri® (amantadine) extended release (ER) capsules by using metrics pertinent to ER dosage forms.…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 32
- Next Page »